A prognostic immune risk score for diffuse large B‐cell lymphoma
Summary We constructed a prognostic score for persons with diffuse large B‐cell lymphoma (DLBCL) based on infiltrating immune cells. Data of 956 consecutive subjects were retrieved from the Gene Expression Omnibus database and assigned to training (GSE10846, n = 305) or validation (GSE87371 n = 206...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2021-07, Vol.194 (1), p.111-119 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 119 |
|---|---|
| container_issue | 1 |
| container_start_page | 111 |
| container_title | British journal of haematology |
| container_volume | 194 |
| creator | Ma, Shu‐Yun Tian, Xiao‐Peng Cai, Jun Su, Ning Fang, Yu Zhang, Yu‐Chen Wang, Jin‐Ni Peter Gale, Robert Cai, Qing‐Qing |
| description | Summary
We constructed a prognostic score for persons with diffuse large B‐cell lymphoma (DLBCL) based on infiltrating immune cells. Data of 956 consecutive subjects were retrieved from the Gene Expression Omnibus database and assigned to training (GSE10846, n = 305) or validation (GSE87371 n = 206 and GSE117556 n = 445 combined) cohorts. Proportions of non‐lymphoma cells in the sample were inferred using the ESTIMATE algorithm. An immune risk score was constructed comprised of eight types of non‐lymphoma immune cells calculated using the CIBERSORT algorithm. Five‐year survival of subjects with an immune risk score ≤ 0·45 in the training cohort was better than that of subjects with a score > 0·45 (hazard ratio [HR] = 3·99; 95% confidence interval [CI] = 2·74, 5·82; P |
| doi_str_mv | 10.1111/bjh.17478 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2522191679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2545970999</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3888-cafb4a749bc834ddb03890f9876674e2c188da15ab631dc4105f34a0a32c4de3</originalsourceid><addsrcrecordid>eNp10L1OwzAUBWALgWgpDLwAssQCQ1pf20nssa2AgiqxdLccx2lT8lPsRqgbj8Az8iSkpDAgcZe7fDo6OghdAhlCe6NkvRpCzGNxhPrAojCgwOEY9QkhcQCEix46835NCDASwinqMSY5pRL6aDLGG1cvq9pvc4Pzsmwqi13uX7A3tbM4qx1O8yxrvMWFdkuLJ5_vH8YWBS525WZVl_ocnWS68Pbi8AdocX-3mM6C-fPD43Q8DwwTQgRGZwnXMZeJEYynaUKYkCSTIo6imFtqQIhUQ6iTiEFqOJAwY1wTzajhqWUDdNPFtn1fG-u3qsz9voiubN14RUNKQUIUy5Ze_6HrunFVW65VPJQxkXKvbjtlXO29s5nauLzUbqeAqP2uqt1Vfe_a2qtDYpOUNv2VP0O2YNSBt7ywu_-T1ORp1kV-AWGrgOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2545970999</pqid></control><display><type>article</type><title>A prognostic immune risk score for diffuse large B‐cell lymphoma</title><source>MEDLINE</source><source>Wiley Journals</source><source>Wiley Free Content</source><creator>Ma, Shu‐Yun ; Tian, Xiao‐Peng ; Cai, Jun ; Su, Ning ; Fang, Yu ; Zhang, Yu‐Chen ; Wang, Jin‐Ni ; Peter Gale, Robert ; Cai, Qing‐Qing</creator><creatorcontrib>Ma, Shu‐Yun ; Tian, Xiao‐Peng ; Cai, Jun ; Su, Ning ; Fang, Yu ; Zhang, Yu‐Chen ; Wang, Jin‐Ni ; Peter Gale, Robert ; Cai, Qing‐Qing</creatorcontrib><description>Summary
We constructed a prognostic score for persons with diffuse large B‐cell lymphoma (DLBCL) based on infiltrating immune cells. Data of 956 consecutive subjects were retrieved from the Gene Expression Omnibus database and assigned to training (GSE10846, n = 305) or validation (GSE87371 n = 206 and GSE117556 n = 445 combined) cohorts. Proportions of non‐lymphoma cells in the sample were inferred using the ESTIMATE algorithm. An immune risk score was constructed comprised of eight types of non‐lymphoma immune cells calculated using the CIBERSORT algorithm. Five‐year survival of subjects with an immune risk score ≤ 0·45 in the training cohort was better than that of subjects with a score > 0·45 (hazard ratio [HR] = 3·99; 95% confidence interval [CI] = 2·74, 5·82; P < 0·001). HR in the validation cohort was HR = 2·17 (1·47, 3·21; P < 0·001). Enrichment analyses indicated correlations with genes controlling immune‐related biological processes and pathways. A nomogram comprised of the immune risk score and most covariates including age, lactate dehydrogenase concentration (LDH), lymphoma‐type (germinal centre B cell [GCB] versus non‐GCB), Eastern Cooperative Oncology Group performance status (ECOG‐PS) and rituximab therapy had a C‐statistic of 0·76 compared with C‐statistics of 0·69 and 0·69 for the International Prognostic Index (IPI) and Revised International Prognostic Index (R‐IPI). These data indicate the immune risk score is an accurate, independent survival predictor in persons with DLBCL.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.17478</identifier><identifier>PMID: 33942291</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Algorithms ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B-cell lymphoma ; Databases, Genetic ; diffuse large B‐cell lymphoma ; Female ; Gene expression ; Gene Ontology ; Germinal Center - pathology ; Hematology ; Humans ; immune risk score ; Kaplan-Meier Estimate ; L-Lactate dehydrogenase ; L-Lactate Dehydrogenase - blood ; Lactic acid ; Lymphocytes, Tumor-Infiltrating - classification ; Lymphocytes, Tumor-Infiltrating - pathology ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - drug therapy ; Lymphoma, Large B-Cell, Diffuse - immunology ; Lymphoma, Large B-Cell, Diffuse - mortality ; Lymphoma, Large B-Cell, Diffuse - pathology ; Male ; micro‐environment ; Middle Aged ; Neoplasm Proteins - blood ; Nomograms ; Prognosis ; Risk Assessment ; Rituximab ; Severity of Illness Index ; Stromal Cells - pathology ; Tumor Microenvironment - immunology</subject><ispartof>British journal of haematology, 2021-07, Vol.194 (1), p.111-119</ispartof><rights>2021 British Society for Haematology and John Wiley & Sons Ltd.</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3888-cafb4a749bc834ddb03890f9876674e2c188da15ab631dc4105f34a0a32c4de3</citedby><cites>FETCH-LOGICAL-c3888-cafb4a749bc834ddb03890f9876674e2c188da15ab631dc4105f34a0a32c4de3</cites><orcidid>0000-0001-5447-3282 ; 0000-0003-3378-1520 ; 0000-0002-9156-1676</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.17478$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.17478$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33942291$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Shu‐Yun</creatorcontrib><creatorcontrib>Tian, Xiao‐Peng</creatorcontrib><creatorcontrib>Cai, Jun</creatorcontrib><creatorcontrib>Su, Ning</creatorcontrib><creatorcontrib>Fang, Yu</creatorcontrib><creatorcontrib>Zhang, Yu‐Chen</creatorcontrib><creatorcontrib>Wang, Jin‐Ni</creatorcontrib><creatorcontrib>Peter Gale, Robert</creatorcontrib><creatorcontrib>Cai, Qing‐Qing</creatorcontrib><title>A prognostic immune risk score for diffuse large B‐cell lymphoma</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
We constructed a prognostic score for persons with diffuse large B‐cell lymphoma (DLBCL) based on infiltrating immune cells. Data of 956 consecutive subjects were retrieved from the Gene Expression Omnibus database and assigned to training (GSE10846, n = 305) or validation (GSE87371 n = 206 and GSE117556 n = 445 combined) cohorts. Proportions of non‐lymphoma cells in the sample were inferred using the ESTIMATE algorithm. An immune risk score was constructed comprised of eight types of non‐lymphoma immune cells calculated using the CIBERSORT algorithm. Five‐year survival of subjects with an immune risk score ≤ 0·45 in the training cohort was better than that of subjects with a score > 0·45 (hazard ratio [HR] = 3·99; 95% confidence interval [CI] = 2·74, 5·82; P < 0·001). HR in the validation cohort was HR = 2·17 (1·47, 3·21; P < 0·001). Enrichment analyses indicated correlations with genes controlling immune‐related biological processes and pathways. A nomogram comprised of the immune risk score and most covariates including age, lactate dehydrogenase concentration (LDH), lymphoma‐type (germinal centre B cell [GCB] versus non‐GCB), Eastern Cooperative Oncology Group performance status (ECOG‐PS) and rituximab therapy had a C‐statistic of 0·76 compared with C‐statistics of 0·69 and 0·69 for the International Prognostic Index (IPI) and Revised International Prognostic Index (R‐IPI). These data indicate the immune risk score is an accurate, independent survival predictor in persons with DLBCL.</description><subject>Adult</subject><subject>Aged</subject><subject>Algorithms</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B-cell lymphoma</subject><subject>Databases, Genetic</subject><subject>diffuse large B‐cell lymphoma</subject><subject>Female</subject><subject>Gene expression</subject><subject>Gene Ontology</subject><subject>Germinal Center - pathology</subject><subject>Hematology</subject><subject>Humans</subject><subject>immune risk score</subject><subject>Kaplan-Meier Estimate</subject><subject>L-Lactate dehydrogenase</subject><subject>L-Lactate Dehydrogenase - blood</subject><subject>Lactic acid</subject><subject>Lymphocytes, Tumor-Infiltrating - classification</subject><subject>Lymphocytes, Tumor-Infiltrating - pathology</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - drug therapy</subject><subject>Lymphoma, Large B-Cell, Diffuse - immunology</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Male</subject><subject>micro‐environment</subject><subject>Middle Aged</subject><subject>Neoplasm Proteins - blood</subject><subject>Nomograms</subject><subject>Prognosis</subject><subject>Risk Assessment</subject><subject>Rituximab</subject><subject>Severity of Illness Index</subject><subject>Stromal Cells - pathology</subject><subject>Tumor Microenvironment - immunology</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L1OwzAUBWALgWgpDLwAssQCQ1pf20nssa2AgiqxdLccx2lT8lPsRqgbj8Az8iSkpDAgcZe7fDo6OghdAhlCe6NkvRpCzGNxhPrAojCgwOEY9QkhcQCEix46835NCDASwinqMSY5pRL6aDLGG1cvq9pvc4Pzsmwqi13uX7A3tbM4qx1O8yxrvMWFdkuLJ5_vH8YWBS525WZVl_ocnWS68Pbi8AdocX-3mM6C-fPD43Q8DwwTQgRGZwnXMZeJEYynaUKYkCSTIo6imFtqQIhUQ6iTiEFqOJAwY1wTzajhqWUDdNPFtn1fG-u3qsz9voiubN14RUNKQUIUy5Ze_6HrunFVW65VPJQxkXKvbjtlXO29s5nauLzUbqeAqP2uqt1Vfe_a2qtDYpOUNv2VP0O2YNSBt7ywu_-T1ORp1kV-AWGrgOQ</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Ma, Shu‐Yun</creator><creator>Tian, Xiao‐Peng</creator><creator>Cai, Jun</creator><creator>Su, Ning</creator><creator>Fang, Yu</creator><creator>Zhang, Yu‐Chen</creator><creator>Wang, Jin‐Ni</creator><creator>Peter Gale, Robert</creator><creator>Cai, Qing‐Qing</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5447-3282</orcidid><orcidid>https://orcid.org/0000-0003-3378-1520</orcidid><orcidid>https://orcid.org/0000-0002-9156-1676</orcidid></search><sort><creationdate>202107</creationdate><title>A prognostic immune risk score for diffuse large B‐cell lymphoma</title><author>Ma, Shu‐Yun ; Tian, Xiao‐Peng ; Cai, Jun ; Su, Ning ; Fang, Yu ; Zhang, Yu‐Chen ; Wang, Jin‐Ni ; Peter Gale, Robert ; Cai, Qing‐Qing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3888-cafb4a749bc834ddb03890f9876674e2c188da15ab631dc4105f34a0a32c4de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Algorithms</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B-cell lymphoma</topic><topic>Databases, Genetic</topic><topic>diffuse large B‐cell lymphoma</topic><topic>Female</topic><topic>Gene expression</topic><topic>Gene Ontology</topic><topic>Germinal Center - pathology</topic><topic>Hematology</topic><topic>Humans</topic><topic>immune risk score</topic><topic>Kaplan-Meier Estimate</topic><topic>L-Lactate dehydrogenase</topic><topic>L-Lactate Dehydrogenase - blood</topic><topic>Lactic acid</topic><topic>Lymphocytes, Tumor-Infiltrating - classification</topic><topic>Lymphocytes, Tumor-Infiltrating - pathology</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - drug therapy</topic><topic>Lymphoma, Large B-Cell, Diffuse - immunology</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Male</topic><topic>micro‐environment</topic><topic>Middle Aged</topic><topic>Neoplasm Proteins - blood</topic><topic>Nomograms</topic><topic>Prognosis</topic><topic>Risk Assessment</topic><topic>Rituximab</topic><topic>Severity of Illness Index</topic><topic>Stromal Cells - pathology</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Shu‐Yun</creatorcontrib><creatorcontrib>Tian, Xiao‐Peng</creatorcontrib><creatorcontrib>Cai, Jun</creatorcontrib><creatorcontrib>Su, Ning</creatorcontrib><creatorcontrib>Fang, Yu</creatorcontrib><creatorcontrib>Zhang, Yu‐Chen</creatorcontrib><creatorcontrib>Wang, Jin‐Ni</creatorcontrib><creatorcontrib>Peter Gale, Robert</creatorcontrib><creatorcontrib>Cai, Qing‐Qing</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Shu‐Yun</au><au>Tian, Xiao‐Peng</au><au>Cai, Jun</au><au>Su, Ning</au><au>Fang, Yu</au><au>Zhang, Yu‐Chen</au><au>Wang, Jin‐Ni</au><au>Peter Gale, Robert</au><au>Cai, Qing‐Qing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prognostic immune risk score for diffuse large B‐cell lymphoma</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2021-07</date><risdate>2021</risdate><volume>194</volume><issue>1</issue><spage>111</spage><epage>119</epage><pages>111-119</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
We constructed a prognostic score for persons with diffuse large B‐cell lymphoma (DLBCL) based on infiltrating immune cells. Data of 956 consecutive subjects were retrieved from the Gene Expression Omnibus database and assigned to training (GSE10846, n = 305) or validation (GSE87371 n = 206 and GSE117556 n = 445 combined) cohorts. Proportions of non‐lymphoma cells in the sample were inferred using the ESTIMATE algorithm. An immune risk score was constructed comprised of eight types of non‐lymphoma immune cells calculated using the CIBERSORT algorithm. Five‐year survival of subjects with an immune risk score ≤ 0·45 in the training cohort was better than that of subjects with a score > 0·45 (hazard ratio [HR] = 3·99; 95% confidence interval [CI] = 2·74, 5·82; P < 0·001). HR in the validation cohort was HR = 2·17 (1·47, 3·21; P < 0·001). Enrichment analyses indicated correlations with genes controlling immune‐related biological processes and pathways. A nomogram comprised of the immune risk score and most covariates including age, lactate dehydrogenase concentration (LDH), lymphoma‐type (germinal centre B cell [GCB] versus non‐GCB), Eastern Cooperative Oncology Group performance status (ECOG‐PS) and rituximab therapy had a C‐statistic of 0·76 compared with C‐statistics of 0·69 and 0·69 for the International Prognostic Index (IPI) and Revised International Prognostic Index (R‐IPI). These data indicate the immune risk score is an accurate, independent survival predictor in persons with DLBCL.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>33942291</pmid><doi>10.1111/bjh.17478</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-5447-3282</orcidid><orcidid>https://orcid.org/0000-0003-3378-1520</orcidid><orcidid>https://orcid.org/0000-0002-9156-1676</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2021-07, Vol.194 (1), p.111-119 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2522191679 |
| source | MEDLINE; Wiley Journals; Wiley Free Content |
| subjects | Adult Aged Algorithms Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-cell lymphoma Databases, Genetic diffuse large B‐cell lymphoma Female Gene expression Gene Ontology Germinal Center - pathology Hematology Humans immune risk score Kaplan-Meier Estimate L-Lactate dehydrogenase L-Lactate Dehydrogenase - blood Lactic acid Lymphocytes, Tumor-Infiltrating - classification Lymphocytes, Tumor-Infiltrating - pathology Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - immunology Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - pathology Male micro‐environment Middle Aged Neoplasm Proteins - blood Nomograms Prognosis Risk Assessment Rituximab Severity of Illness Index Stromal Cells - pathology Tumor Microenvironment - immunology |
| title | A prognostic immune risk score for diffuse large B‐cell lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T01%3A36%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prognostic%20immune%20risk%20score%20for%20diffuse%20large%20B%E2%80%90cell%20lymphoma&rft.jtitle=British%20journal%20of%20haematology&rft.au=Ma,%20Shu%E2%80%90Yun&rft.date=2021-07&rft.volume=194&rft.issue=1&rft.spage=111&rft.epage=119&rft.pages=111-119&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.17478&rft_dat=%3Cproquest_cross%3E2545970999%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2545970999&rft_id=info:pmid/33942291&rfr_iscdi=true |